9 results about "Tyrosine hydroxylase" patented technology

The invention belongs to the technical field of disease and pest control, discloses application of tyrosine hydroxylase as a target spot in prodenia litura pest control for the first time, screens out a dopamine synthesis inhibitor AMPT aiming at tyrosine hydroxylase, and develops a technology for efficiently controlling prodenia litura. According to the technology, AMPT is injected into the fourth-instar larvae of the prodenia litura, and the melanin deposition of the exoskeleton of the larvae is reduced, the color of the body surface becomes light and the athletic ability is remarkably reduced by utilizing the dopamine synthesis inhibition function of AMPT. On one hand, reduction of melanin deposition weakens the environmental adaptability of pests, and the exposure risk of the pests in the natural environment is increased; on the other hand, the migration behavior of the pests is directly influenced by the decline of the exercise ability, and the population diffusion and hazard range of the pests are limited. The dual-action mechanism reduces the environmental adaptability and survival competitiveness of the pests, and provides a new strategy for green prevention and control.

The invention belongs to the technical field of medicines, and discloses application of poliumoside to prevention and treatment of Parkinson's disease. Specifically, the invention discloses application of poliumoside as a compound shown in a formula (I) in the aspect of preventing and treating Parkinson's disease. Pharmacological experiments prove that after 14 days of administration of the poliumoside, the impairment of motor coordination function caused by MPTP-induced Parkinson's disease can be obviously improved, the reduction of the expression level of brain nigra tyrosine hydroxylase caused by MPTP is improved, and the result shows that the poliumoside has obvious pharmacological activity for preventing and treating Parkinson's disease. Therefore, poliumoside can be used for preparing the medicine for preventing and treating Parkinson's disease, and has high clinical application value and development prospect.

The invention discloses application of C-176 in preparation of a medicine for treating Parkinson's disease, belongs to the technical field of medicines, and particularly relates to a medicine for treating Parkinson's disease, which comprises C-176 or a pharmaceutical salt thereof. As an STING inhibitor C-176 is adopted as a medicine for treating Parkinson's disease, 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) is utilized to construct an animal model of Parkinson's disease, and animal experiments prove that the expression of STING protein in striatum of a mouse in the model is increased, and the expression of tyrosine hydroxylase (TH) is reduced at the same time. The C-176 can improve the expression level of TH in striatum of a Parkinson model mouse. A behavioral experiment result proves that the C-176 can improve the movement and movement coordination ability of a model mouse and relieve the anxiety behavior of the model mouse.

The invention discloses an application of a smoked plum general flavone extract in preparation of a medicine for preventing or treating Parkinson's disease, and relates to the field of medicines.The smoked plum general flavone extract is prepared through a method comprising the following steps that smoked plum serves as a raw material and is extracted through an ethanol water solution, an extracting solution is concentrated and then adsorbed through macroporous resin, and the smoked plum general flavone extract is obtained. Eluting with an ethanol water solution, collecting the eluent, concentrating and drying; the application shows a definite neuroprotective effect in two classical animal models of Parkinson's disease, can reduce loss and morphological damage of brain nigra neurons in model animals, and significantly increases the number of tyrosine hydroxylase positive cells in nigra of the model animals, which indicates that the application has a protective effect on dopaminergic neurons, and can be used for preparing drugs for treating Parkinson's disease. Motion coordination and balance capacity of model animals can be obviously improved in a dose-dependent manner, the potential of improving disease progress is achieved, and a new candidate substance is provided for developing Parkinson's disease treatment drugs with a neuroprotective effect.

This invention discloses the application of bimatoprost in the preparation of drugs for the prevention and / or treatment of Parkinson's disease, within the field of drug reuse. Bimatoprost is a prostaglandin F2α analog, currently mainly used for glaucoma and eyelash growth. This invention has found that bimatoprost can improve Parkinson's disease-related behavioral disorders, increase the expression of tyrosine hydroxylase, a protein associated with dopaminergic neurons in the substantia nigra, and reduce the abnormal accumulation of α-synuclein, thus exhibiting good ameliorative and protective effects against Parkinson's disease. This invention provides a new drug option for the treatment of Parkinson's disease.

The invention belongs to the technical field of biological medicine, and discloses application of radix paeoniae alba polysaccharide to preparation of a medicine for preventing and treating Parkinson's disease, radix paeoniae alba polysaccharide with the purity larger than or equal to 97% is extracted and prepared through a water extraction and alcohol precipitation method, 50-200 mg / kg of radix paeoniae alba polysaccharide can improve dyskinesia of a model mouse, and 100 mg / kg is the optimal administration dosage; meanwhile, the radix paeoniae alba polysaccharide can remarkably increase the number of tyrosine hydroxylase positive neurons in the compact part of nigra of a model mouse, effectively protect dopaminergic neurons and inhibit progressive degeneration death of the dopaminergic neurons, and the prevention and treatment effect is achieved from the core pathological mechanism level of the Parkinson's disease. According to the application of the radix paeoniae alba polysaccharide in preparation of the medicine for preventing and treating the Parkinson's disease, the radix paeoniae alba polysaccharide serves as a natural plant active ingredient, is low in toxic and side effect and good in biocompatibility and can be prepared into a single or compound preparation, a brand-new natural medicine candidate is provided for preventing and treating the Parkinson's disease, and the radix paeoniae alba raw material in the medicine is easy to obtain and controllable in cost; and the method has a good industrialization prospect.

A gene sequence construct used for the treatment of central nervous system diseases: by means of the construction of an auto-processing expression vector, tyrosine hydroxylase (TH), GTP-cyclohydrolase I (GCH1), aromatic amino acid dopa decarboxylase (AADC), and so on may be simultaneously expressed; proteins are connected by means of an auto-processing unit (APU); the use of a viral vector to introduce the construct into a target cell may ultimately result in the high-efficiency expression of tyrosine hydroxylase (TH), GTP-cyclohydrolase I (GCH1), aromatic amino acid dopa decarboxylase (AADC), and so on having independent functions, being used in the prevention or treatment of Parkinson's disease, Alzheimer's disease and other neurodegenerative diseases.

Provided are gene therapy vectors for the treatment of Parkinson's disease and uses thereof. Specifically, adeno-associated virus (AAV) vectors are provided for the treatment of Parkinson's disease that can simultaneously express functional tyrosine hydroxylase (TH), GTP-cyclization hydrolase 1 (GCH1), and aromatic amino acid dopa decarboxylase (AADC) to promote dopamine synthesis. The invention also provides AAV virus particles containing the AAV vector, a composition containing the AAV vector or the AAV virus particles, and application of the AAV vector, the AAV virus particles and the composition in preparation of medicines for preventing or treating Parkinson's disease.

The invention discloses a construction method and application of a silkworm ultraviolet damage model, and belongs to the technical field of biomedical model construction. The method comprises the steps that bombyx mori with a dominant P site (+ P) reserved in a genome is placed in an ultraviolet irradiation box, UVC irradiation is used for 10-15 min or UVB irradiation is used for 6-8 h, quantifiable melanin deposition specifically appears within 6-24 h after irradiation, and the reliability of the model is evaluated by measuring the epidermal melanin content and the expression level of tyrosine hydroxylase or dopa pigment decarboxylase. The model can be used for evaluating the ultraviolet radiation resistance of sunscreen products and screening ultraviolet radiation resistant products. The method has the remarkable advantages of short period, low cost and no ethical dispute.